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Objective: To study and evaluate changes in the gyrA gene and the outer-membrane protein patterns in  relation to  
evolution of resistance against the quinolones in Enterobacter cloacae. 
Methods: Strains expressing gyrA-mediated quinolone resistance become susceptible to  quinolones upon insertion of 
the plasmid pNJR3-2. This plasmid (containing wild-type Escberichia coliquinolone-susceptible DNA gyrase A subunits) 
and pLA2917 (the vector) were introduced into 10 resistant or moderately susceptible clinical isolates of Enterobacter 
cloacae by conjugation. The transconjugants, the original isolates, the plasmid and the vector control were screened for 
susceptibility t o  ofloxacin, ciprofloxacin and sparfloxacin. Additionally, examinations of the outer-membrane proteins 
were performed. 
Results: A reduction of MlCs by a factor of 8-32 was found for the transconjugants of five Enterobacter cioacae isolates 
in the presence of the gene probe, suggesting that these isolates harbored mutations in gyrA. No discernible difference 
in the patterns of outer-membrane proteins of sensitive and resistant strains could be detected. 
Conclusions: It seems that changes in the target site such as alterations in gyrA are important factors leading to  a 
change in  the susceptibility of bacteria to  the quinolones, whereas there were no evident changes in the outer-membrane 
proteins to  account for evolution of resistance. 
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INTRODUCTION 
Since the synthesis of nalidixic acid [l], a large number 
of quinolone derivatives have been synthesized and 
evaluated for their antibacterial activities [2,3]. Among 
the most potent of these drugs are the fluoro- 
quinolones, such as ofloxacin and ciprofloxacin, which 
are established therapeutic agents [4]. The molecular 
targets for the quinolone drugs in most bacteria1 species 
are thought to be DNA gyrase [S ] ,  the bacterial enzyme 
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which supercoils DNA by using the free energy of ATP 
hydrolysis, and topoisomerase IV [6]. 
Due to their almost unrestricted use, resistance 
against the fluoroquinolones has begun to appear in a 
variety o f  microorganisms. At least three main mech- 
anisms of quinolone resistance have been recognized: 
mutations in the gyrA or gyrB genes [7-91, mutations in 
the pavC or pavE subunits of topoisomerase IV [lo-121 
and mutations causing poor drug transport [13-15]. 
However, mechanisms of resistance at  the molecular 
level are not yet entirely elucidated. One of the micro- 
organisms in which resistance to the fluoroquinolones 
has been observed is Enterobacter cloacae, an important 
agent in the etiology of nosocomial infections. While 
in the case of other microorganisms, such as Escherichia 
coli, mutations in the bacterial gyrase have been 
recognized as constituting a major mechanism for the 
development of resistance [9,16], it remains to be seen 
whether one mechanism alone or a combination of 
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mechanisms is involved in resistance in Entevobactev 
cloacae. 
In this study, clinical isolates of Evltevobactev cloacue 
were tested for their susceptibility to several quino- 
lones. Strains which proved to be resistant were 
conjugated with a gene probe containing g p 4  
encoding Esrheviclzia coli wild-type quinolone- 
susceptible DNA gyrase A subunit. Additionally, the 
patterns of the outer-membrane proteins (OMPs) of 
the resictant and several susceptible strains were 
determined and compared. 
MATERIALS AND METHODS 
Antimicrobial agents 
Antibiotics were provided by the following pharma- 
ceutical companies: nalidixic acid (Sterling Winthrop, 
France), pipeniidic acid (Madaus, Austria), cipro- 
floxacin and Bay y 31 18 (Bayer, Austria), nodoxacin 
and cefoxitin (Merck, Sharp & Dohme, Austria), 
pefloxacin (Kh6ne Poulence, France), ofloxacin 
(Hoechst Roussel, Austria), fleroxacin (Hofniann 
LaKoche, Austria), sparfloxacin (KhBne Poulence, 
France), lomefloxacin (D. Searle & Co., UK), 
rufloxacin (Medioloanum, Farmateutici, Italy), E-4868 
(Esteve, Spain), tetracycline (Lederle, Austria), 
triinethoprim (Roche, Austria) and chloramphenicol 
(Warner Lambert, USA). The drugs were stored, 
dissolved and diluted according to the recommen- 
dations of the manufacturers. 
Bacterial strains 
Ninety-two strains of Enterobactev cloacae isolated from 
different specimens were collected during 1 year in the 
General Hospital of Vienna. All isolates were identified 
by standard microbiological methods and stored in 
liquid nitrogen. O f  the 92 strains, 10 strains were found 
to be resistant or moderately resistant to the quinolones 
and consequently chosen for conjugation and OMP 
experiments. Escherichia Cali ATCC 25922, used as 
susceptibility test control, was found to be within the 
expected range during the period of investigation. 
Enferobactev cloacae NCTC 10005 and Escherichia cooli S- 
17 were obtained from L. Piddock (University of 
Birmingham). 
Determination of MlCs 
MICs were determined by a standardized broth dilution 
technique. Mueller-Hinton broth (Merck) was the 
standard medium [17,18]. Wells were inoculated with 
a standardized suspension of the fresh isolate to produce 
a final concentration of 5 x 10' colony-forming units 
(CFU) per inL of broth. MIC breakpoints for resistance 
were as follows: ciprofloxacin, 2 1 nig/L; norfloxacin, 
2 1 nig/L; pefloxacin, 2 2  mg/L; ofloxacin, 2 2  mg/L; 
loniefloxacin, 2 2  mg/L; sparfloxacin, 2 1 mg/L; nali- 
dixic acid, 2 3 2  mg/L; pipeniidic acid, 1 8  mg/L; 
fleroxacin, 2 8  nig/L; rufloxacin, 2 8  mg/L; cefoxitin, 
2 3 2  mg/L; chloramphenicol, 2 16 mg/L; trimetho- 
prim, 2 4  mg/L; tetracycline, 2 8  mg/L. 
Preparations of outer-membrane proteins 
The outer-membrane proteins of all strains were 
prepared as described by Piddock et a1 [19]. All strains 
were grown to late logarithmic phase and 150 mL cell 
culture was harvested by centrifuging a t  30002 a t  4°C 
for 13 min in a Rotanta TKC (Hettich) centrifuge. 
The pellet was resuspended in 50 mM sodium phos- 
phate buffer pH 7 and recentrifuged. The cell pellet 
was resuspended in 4 mL sodium phosphate buffer 
(50 mM, pH 7) and frozen at -20°C. The pellet was 
thawed at room temperature and sonicated on ice for 
4x30 s with intermittent 30 s cooling periods with a 
Sonoplus HD 200 (Bandelin). To remove any unbroken 
cells, the sonicate was centrifuged at 40002 at 4°C for 
10 min in a microliter (Hettich) centrifuge. The 
supernatant was transferred to a fresh tube and 
centrifuged at 13 000g for 30 min at 4% The pellet 
was resuspended in 400 pL 2% sarcosyl (Sigma), 
incubated at room temperature for 30 min, and then 
recentrifuged a t  13 0002 for 30 min at 10°C. The pellet 
of the OMP was resuspended in 50pL buffer and 
frozen at -20°C. Protein concentration was deter- 
mined by the Lowry assay [20]. 
Sodium dodecylsulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
The OMPs were analyzed by SDS-PAGE with a 
Midget Electrophoresis Unit (LKB Pharmacia). The 
fractions were solubilized in double-strength sample 
buffer (0.5 M Tris-HC1 (pH 6.8)/10% glycerol/2% 
SDS/5% P-niercaptoethanol) and heated a t  l00OC for 
10 min. The stacking gel contained 4%) acrylaniide in 
0.5 M Tris-HC1 (pH 6.8)/1% SDS. The resolving gel 
contained 7.5% acrylamide. Electrophoresis was carried 
out at a constant voltage of 10 niV per gel. T h e  gels 
were stained with Coomassie blue (Phast Gel Blue R). 
Conjugation experiments 
The Eschevichia coli S-17 strains containing pNJR3-2 or 
pLA2917 (plasmids obtained from L. Piddock, 
Birmingham, UK) were inoculated into broth plus 
tetracycline (5 mg/L), and the clinical isolates were 
inoculated into broth without antibiotics; incubation 
was overnight at  37OC. Donors and recipients (0.5 mL 
of each) were mixed in an Eppendorftube, centrifuged 
at 13 000 rev/niin for 5 min and resuspended in 50 pL 
0.15 M NaC1. The mixture was spread onto Mueller- 
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Luria agar plates and incubated for 5 h at 37OC to allow 
mating between the strains, after which the bacterial 
growth was removed to phosphate-buffered saline. 
Appropriate dilutions ofthe mating mixture were made 
and 100 pL of each dilution spread onto selective 
MacConkey agar plates. Ten transconjugant colonies of 
each isolate were selected by their tetracycline resist- 
ance, also encoded by the plasmid, and screened for 
susceptibility The selective plates for the Enterobacter 
cloacae isolates contained 20 mg, 100 mg or 200 mg of 
tetracycline per liter. Transconjugants were purified on 
selection media and identified again as Enterobacter 
cloacae by the API test system. To maintain the plasmids, 
tetracycline (10 mg/L for Esckerickia coli S-17 and 
20 mg/L for the Enterobacter cloacae transconjugants) was 
added to the medium. The MICs of several quinolones 
were determined for each strain in the presence or 
absence of each plasmid. 
Plasmid preparation and gel electrophoresis of plasmid 
After plasmid extraction as described by Bennett et al 
[21] and after cleavage with HindIII (USB) restriction 
enzyme, the presence of the pNJR3-2 plasmid was 
confirmed by agarose electrophoresis and staining with 
ethidium bromide. 
RESULTS 
Table 1 summarizes the results of the MIC determin- 
ations, comparing the activities of the 12 quinolones 
against 92 strains of Enterobacter cloacae. Ciprofloxacin 
and Bay y 3118 were the most active fluoroquinolones, 
followed by sparfloxacin, ofloxacin and norfloxacin. 
Nalidixic and pipemidic acid, as representatives of the 
more hydrophobic, unfluorinated quinolones, were 
Table 1 
Enterobacter cloacae isolates 
I n  vitro activities of 12 quinolones against 
MIC (ma/L) (n=92) 
Antibacterial ageiit Range MlCio MICm 
Nalidixic acid 
Plpemidc acid 
Norfloxacin 
Pefloxacin 
Fleroxacin 
Lomefloxacin 
Ciprofloxacin 
Ofloxacin 
Sparfloxacin 
Rufloxacin 
Bay y 3118 
E-4868 
4 to 2256 
1 to 2256 
50.01-16 
10.01-32 
5 0.0 1-32 
50.01-16 
50.01-4 
10.01-16 
5 0 . 0 1 4  
10.01-1 
0.25 to 2256 
0.03-64 
8 
2 
0.06 
0.12 
0.25 
0.12 
50.01 
0.12 
0.03 
1 
50.01 
0.25 
32 
8 
0.5 
2 
1 
0.5 
0.12 
1 
0.25 
2 
0.12 
1 
also tested. These agents demonstrated the lowest in 
vitro activity. In total, 10 strains were found to be 
resistant or moderately resistant; their MIC values 
against the tested quinolones and four structurally 
unrelated antimicrobial agents are shown in Table 2. 
Among those strains, isolates with high-level 
resistance to ofloxacin (two strains, MIC 2 4  mg/L), to 
norfloxacin (two strains, MIC 2 8  mg/L), to cipro- 
floxacin (one strain, MIC 4 mg/L) and to nalidixic 
acid (nine strains, MIC 2 3 2  mg/L) were found. Two 
strains (E89 and E105) were resistant to the whole 
quinolone class. Both strains were isolated from patients 
who had previously been treated with fluoro- 
quinolones. Strain El08  showed decreased suscepti- 
bility to the fluoroquinolones, but was sensitive to 
nalidixic and pipemidic acid. After introduction of the 
plasmids pNJR3-2 and pLA2917 (control vector) into 
Table 2 
antimicrobial agents 
Susceptibility of resistant Enterobacter cloacae isolates (n = 10) t o  12 quinolones and four structurally unrelated 
MIC (mg1L) 
BAYy 
Strain NAL PIP N O R  PEF FLR LOM CIP OFX SFX RUF 3118 E 4868 COX CMP TMP TET 
~~ ~~ 
NCTC 10005 4 1 0.03 0.03 0.03 0.06 50.01 0.03 50.01 0.5 10.01 0.03 128 4 0.5 1 
E5 32 8 0.5 1 1 0.5 0.12 1 0.25 2 0.06 1 256 64 4 32 
E l 5  32 8 0.25 1 0.5 0.5 0.12 1 0.12 2 0.06 0.5 256 64 4 32 
El9 2256 128 1 8 8 1 0.5 1 1 32 0.25 8 512 16 4 8 
E32 64 8 1 1 1 1 0.12 1 0.25 8 0.25 1 512 64 4 32 
E67 2256 32 1 2 2 2 0.25 1 0.5 16 0.12 2 128 8 0.5 2 
E68 2256 64 1 1 2 2 0.25 2 1 8 0.25 2 128 8 1 2 
E89 2256 2256 16 32 32 16 4 16 8 2256 1 64 512 32 4 16 
El05 2256 128 8 16 8 4 1 4 2 64 1 4 512 64 4 32 
El08 8 2 0.12 0.5 0.5 0.05 0.25 0.25 0.5 2 0.12 1 1024 8 0.5 1 
E l l 0  2256 32 0.5 2 2 2 0.25 1 0.5 16 0.12 1 64 8 2256 2 
NAL, nalidixic acid; PIP, pipemidic acid; N O R ,  nodoxacin; PEE pefloxacin; FLR, fleroxacin; LOM, lomefloxacin; CIP, ciprofloxacin; 
OFX, ofloxacin; SFX, sparfloxacin; RUF, rufloxacin; COX, cefoxitin; CMP, chloramphenicol; TMP, trimethoprim; TET, tetracycline. 
7 8  Cl in ica l  M ic rob io logy  and I n f e c t i o n ,  V o l u m e  4 N u m b e r  2 ,  F e b r u a r y  1998 
Table 3 
teti-acvcline ITET) 
Susceptibility of clinical isolates and their transconjugants to ciprofloxacm (CIP), otloxacin (OFX). spaifloxacin (SFX) and 
MIC (mg/L) 
CIP OFX SFX TET 
Ikfore After Before After Before After Before After 
Str'iiri conjugation conjugation conjugation conjugation conjugation conjugation conjugation conjugation 
E l 9  0.5 0.03 2 0.2s 1 0.06 8 2256 
t h 7  0.25 Sf).01 1 0.06 0.5 0.03 2 256 
Ehi; 0.23 50.01 2 0.06 1 0.06 2 256 
EXY 4 0.25 I0 1 8 0.25 16 2256 
E l 1 0  0.25 50.01 1 0.06 0.5 0.03 2 236 
ES 0 .12  0.12 1 0.5 0.12 0.25 32 2256 
E1.i 0.12 0.12 0.5 0.5 0.12 0.25 32 2256 
E32 0.12 0.12 I 1 0.25 0.25 32 2256 
E l05  1 2 4 8 2 4 32 2256 
El (M 0.25 0.12 0.25 0.25 0.5 0.3-5 1 128 
the 10 strains of Enterobacter doacae by conjugation with 
Escliericliin coli S 17-1, the MIC values of quinolones and 
tetracycline were again determined (Table 3). An 8-32 
fold-reduction of MIC was found for the trans- 
conjugnnts of five resistant Enterobacter rloacar isolates 
(E19, E67, E68, E89 and E l  10) in the presence of the 
plasmid, suggesting that these isolates harbored muta- 
tions in gyvA. Reversion to wild-type susceptibility 
upon insertion of pNJR3-2 was found in E67, E68 and 
El 10, but not in E l 9  and E89. In five isolates (E5, E15, 
E32, ElO.5 and E108) no MIC reduction after con- 
jugation was observed, suggesting a niechanism other 
than mutation in the A subunit of the DNA gyrase. 
The presence of the vector control pLA2917 had no 
effect upon the susceptibility of any of the isolates. 
The presence of the plasmid was confirmed by 
plasmid profiles (digestion of pNJR3-2 with restriction 
nuclease HindIII) (data not shown) and the high-level 
resistance to tetracycline in the transconjugants. 
The OMPs of seven susceptible Giterobacter cloacae 
strains (E42, E44, E45, E.51, E57, E65 and E87) and of 
all resistant strains were determined and compared 
E5 E l 5  E l 9  E32 Eh7 E68 E8Y El05 El08 E l  10 
Figure 1 SDY-PAGE (I 1%) of outer-membrane proteinr of resistant Enterobacter cloacae irolates 
36-37kDa - 
35kDa -t 
E87 E65 E57 E51 E15 E44 E42 
Figure 2 SDS-PAGE (1 1%) of outer-membrane proteins susceptible Entevobncter cloacae lsolatec 
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(Figures 1 and 2). All susceptible strains showed bands 
at  35 and 38 kDa, while two strains had an additional 
band at 36.5 kDA (E51 and E87). The pattern of the 
resistant strains showed bands at 35 kDa, 37 kDa and 
38 kDa. While the band a t  35 kDa was observed in all 
strains, variations in the bands at 37 kDa and 38 kDa  
were seen. 
DISCUSSION 
The fluoroquinolones are potent synthetic agents active 
against a variety of bacterial species in vitro. These 
drugs appear to antagonize the A subunit of the 
bacterial enzyme DNA gyrase and thus block DNA 
replication. Additional incompletely understood pro- 
cesses typically result in the rapid kihng of bacteria. 
Resistance to the fluoroquinolones most probably 
involves mutations altering the A and B subunits of 
DNA gyrase and the parC and parE subunits of 
topoisomerase IV, and other processes such as decreased 
drug penetration [3,22]. Whether one mechanism or a 
combination of mechanisms is required for the 
development of resistance and to what degree this 
development depends on the bacterial species have not 
been sufficiently clarified. 
AIl these mutations conferring quinolone resist- 
ance are located on the bacterial chromosome. Neither 
plasmids encoding quinolone resistance nor complete 
transfer of quinolone resistance in the clinical setting 
has been described yet [23,24]. Lack of transfer may 
reflect the recessive nature of quinolone resistance 
mapping either in the gyrA locus [25] or in loci 
affecting passive permeability. Also, quinolones 
decrease plasmid conjugation from a quinolone-sus- 
ceptible donor bacterium about 1000-fold [26,27], so 
that transfer of a putative plasmid encoding a quinolone 
resistance gene would be retarded in the presence of 
drug. 
These findings of other authors are also reflected 
in the outcome of our study. While different methods 
have been described for the detection of quinolone 
resistance mediated by a change in the gyrase of the 
DNA, Robillard et al [28] cloned the wild-type A 
subunit of the gyrase gene of Escherichia coli to the 
vector pLA2917. This vector and the product pNJR3- 
2 also encode tetracycline and kanamycin resistance and 
are transferred to recipients by conjugation with the 
donor Escherichia coli S17-1. Using this method we 
screened 10 resistant isolates of Enterobacter cloacae for 
mutations in the 8yrA gene. Following the principle of 
dominance, those isolates, whose resistance is gyrA  
mediated regain their susceptibility after conjugation 
with the plasmid. Of the 10 transconjugants, five 
isolates showed a return to susceptibility to the tested 
quinolones. The incomplete return to susceptibility in 
the isolate E89 (and partly also E19) could be explained 
by the assumption of other authors, including Power 
et a1 [29], who examined a single strain of Enterobacter 
cloacae, that high-level resistance for fluoroquinolones 
can involve the acquisition of mutations at multiple loci 
[3]. The resistance ofthe other five strains with no MIC 
reduction can be explained by an additional mechanism 
or by a combination of mechanisms necessary for the 
development of resistance. Also illustrative of the 
difference in these five non-responder strains (and 
perhaps also of the difference in their mechanism of 
resistance) are their MICs with structurally unrelated 
antimicrobial agents. In all these strains, except E l  08 
(with a curious phenotype), there is resistance to 
chloramphenicol and tetracycline. In contrast, the 
five strains that showed return to susceptibility to 
quinolones are susceptible to these agents. 
The phenotype of isolate El08  (NALS, FQR) 
seems to be similar to that of a clinical isolate of 
Escherichia coli highly resistant to fluoroquinolones but 
susceptible to nalidixic acid [23,30]. While in this 
Escherichia coli strain a decrease in outer-membrane 
permeability associated with a peculiar alteration of the 
DNA gyrase was responsible for the unusual pheno- 
type, we could find neither a change in gyrA nor a 
differing OMP pattern in our Enterobacter cloacae isolate. 
One of these additional mechanisms, leading to 
development of resistance against the quinolones, 
looked at most closely is a change in the permeability 
of the outer membrane (OM). This O M  barrier can 
produce significant levels of resistance, especially when 
it is combined with an enzymatic inactivation mech- 
anism. Yet for Auoroquinolones it seems to be true that 
MICs for porin-deficient mutants generally increase 
only 2-4-fold. Acquired resistance in normally 
susceptible bacteria usually involves enzymatic inactiva- 
tion mechanisms, rather than a lowering of O M  
permeability [31]. Our examinations of the OMPs of 
resistant and susceptible strains seem to confirm these 
observations: seven of the 10 resistant strains had all 
their three bands at 35, 37 and 38 kDa, thereby 
showing no correlation with their different sensitivity 
to the quinolones and non-quinolones. In three isolates 
the band at either 37 kDa  or 38 kDa was missing. The 
OMP profiles of the seven sensitive strains also showed 
differences, but all strains had the bands at 35 and 
38 kDa in common. An interpretation of the different 
cross-resistant phenotypes based on OMP modi- 
fications has found no acceptance, although changes in 
the O M  have been frequently observed in niultiresistant 
mutants [32]. All this seems understandable, because 
organisms with intrinsically low-permeability OMS 
must already be equipped with such compensating 
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mechanisms as multitudes of specific diffusion path- 
ways, but the sudden lowering of OM permeability in 
organisms that are not so equipped obviously creates 
disadvantages. 
Other studies seem to implicate an energy- 
dependent efflux system in the cytoplasmic membrane 
of species such as Escherichia coli, Staphylococcus aureus, 
Pseudornonas aeruginosa and Proreus vulgaris as the cause 
of resistance to the quinolones. This system is also held 
responsible for the active release of quinolones out of 
the cytoplasm [33,34]. In contrast, mutations in the 
gyrB gene are considered to be of minor importance for 
resistance, but high levels of resistance in Salmonella 
typlzirnurirtrn to fluoroquinolones, caused by combined 
mutations in g y r A  and gyrB, have been described 
recently [7). 
Finally, the combination of several mechanisms 
seems to be important for the development of resist- 
ance: in strains of Escliericlzia coli with chromosonally 
mediated antibiotic multiresistance, mutation in the 
rtzarA locus has been observed together with a change 
in the coniposition in the OM [35-371. Another com- 
bination, which seems to play a major role in resistance 
to the quinolones, is a combined mutation of the p a r C  
subunit of topoisomerase IV and the gyrA subunit. 
Topoisomerase IV, encoded by p a r C  and p a r E  in, for 
example, Esclzerichia coli, and believed to be located 
in the cytoplasmic membrane, is involved in DNA 
replication but is not as sensitive to fluoroquinolone 
inhibition as is DNA gyrase. Transformation experi- 
ments suggest that mutations in p a r C  may be a 
prerequisite before mutations in gyrA can influence 
resistance levels [10,38]. This contribution of individual 
mechanisms may be the explanation for both the 
differences in the degree of restoration of susceptibility 
and the resistance of the five non-responder strains. 
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